Stelac Advisory Services LLC bought a new stake in Novo Nordisk A/S (NYSE:NVO – Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 60,105 shares of the company’s stock, valued at approximately $2,294,000.
Other institutional investors have also recently added to or reduced their stakes in the company. Scarborough Advisors LLC acquired a new stake in Novo Nordisk A/S in the 1st quarter worth about $26,000. Financial Freedom LLC purchased a new stake in Novo Nordisk A/S in the 3rd quarter valued at about $30,000. Continuum Advisory LLC purchased a new stake in Novo Nordisk A/S in the 2nd quarter valued at about $38,000. Root Financial Partners LLC acquired a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at about $32,000. Finally, Markowski Investments acquired a new position in shares of Novo Nordisk A/S during the 2nd quarter valued at about $43,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
NVO has been the topic of several recent analyst reports. Citigroup reiterated a “neutral” rating on shares of Novo Nordisk A/S in a report on Friday, October 9th. Cfra downgraded shares of Novo Nordisk A/S from a “hold” rating to a “sell” rating and set a $38.00 target price for the company. in a report on Tuesday, September 22nd. BMO Capital Markets set a $40.00 target price on shares of Novo Nordisk A/S and gave the company a “market perform” rating in a report on Monday, October 12th. HSBC reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a research report on Thursday, September 10th. Finally, DZ Bank reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research note on Thursday, August 6th. Five research analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and five have assigned a Sell rating to the company. Based on data from MarketBeat, Novo Nordisk A/S presently has an average rating of “Hold” and a consensus price target of $59.44.
View Our Latest Stock Report on Novo Nordisk A/S
Novo Nordisk A/S Price Performance
NVO stock opened at $40.65 on Wednesday. The stock has a 50-day moving average price of $39.90 and a two-hundred day moving average price of $43.15. Novo Nordisk A/S has a 12-month low of $35.12 and a 12-month high of $64.16. The company has a current ratio of 0.84, a quick ratio of 0.64 and a debt-to-equity ratio of 0.54. The company has a market cap of $181.49 billion, a PE ratio of 10.69, a price-to-earnings-growth ratio of 1.43 and a beta of 0.70.
Novo Nordisk A/S News Roundup
Here’s some of the latest news about NVO:
- Positive Sentiment: A late-stage trial found Wegovy significantly reduced BMI in children ages 6 to under 12 with obesity—a potential future market, as no medication is currently approved for this age group. Article: Novo says Wegovy injection lowers BMI and obesity rates in children in trial
- Neutral Sentiment: Novo launched a refreshed NovoCare program with coverage information, home delivery, an app and patient support for Wegovy users. It could help treatment access and retention, though the near-term financial impact is unclear. Article: Novo launches the new Novocare
- Negative Sentiment: U.S.-traded European ADRs were broadly lower, creating a market headwind for NVO. Separately, coverage comparing Novo with Eli Lilly pointed to Lilly’s faster revenue growth, while another comparison described Novo’s revenue as mostly flat in U.S. dollars—concerns that may weigh on sentiment. Article: European Equities Traded in the US as American Depositary Receipts Tumble in Tuesday Trading
Novo Nordisk A/S Company Profile
Novo Nordisk A/S is a Danish pharmaceutical company focused on treatments for diabetes, obesity and other serious chronic diseases. Its portfolio includes insulin and other diabetes medicines, as well as obesity treatments such as Wegovy and diabetes treatments such as Ozempic and Rybelsus. The company also develops medicines for rare blood and endocrine disorders, including hemophilia and growth disorders. Its products are sold in markets around the world. Novo Nordisk traces its roots to Danish insulin companies founded in the 1920s; the two organizations that became Novo Nordisk merged in 1989.
Read More
- Five stocks we like better than Novo Nordisk A/S
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO – Free Report).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.
